MDV3100

Catalog No. A10562

MDV3100(Enzalutamide)是一种androgen-receptor (AR)拮抗剂。在AR研究中强烈推荐的抑制剂。

Product Citations

Shiv Verma, .et al. Increased cytokine gene expression and cognition risk associated with androgen deprivation therapy, Prostate, 2022, Oct;82(14):1389-1399 PMID: 35821621
Mi Chen, .et al. TRIM33 drives prostate tumor growth by stabilizing androgen receptor from Skp2-mediated degradation, EMBO Rep, 2022, Aug 3;23(8):e53468 PMID: 35785414
Prem P Kushwaha, .et al. Role of solute carrier transporters SLC25A17 and SLC27A6 in acquired resistance to enzalutamide in castration-resistant prostate cancer, Mol Carcinog, 2021, Dec 22 PMID: 34939235

Technical details

Catalog Num	A10562
M. Wt	464.4
Formula	C21H16F4N4O2S
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	915087-33-1
Synonyms	Enzalutamide
SMILES	CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C

Biological Activity

MDV3100(Enzalutamide)是一种androgen-receptor (AR)拮抗剂。在AR研究中强烈推荐的抑制剂。

Targets

Androgen Receptor (LNCaP cells)
36 nM

Solubility *

In vitro	DMSO	Warmed: 89 mg/mL (191.62 mM)
	Water	Insoluble
	Ethanol	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	21.53 mL	107.67 mL	215.33 mL
0.5 mM	4.31 mL	21.53 mL	43.07 mL
1 mM	2.15 mL	10.77 mL	21.53 mL
5 mM	0.43 mL	2.15 mL	4.31 mL

*The above data is based on the productmolecular weight 464.4. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.